TUSTIN, Calif., Dec. 21, 2011 /PRNewswire/ -- Radient Pharmaceuticals Corporation (OTCQX:RXPC.PK - News) (OTCPK:RXPC.PK - News), a developer and marketer of cancer tests, today announces it has expanded its distribution agreement with UniPharma Taiwan headquartered in Taipei, Taiwan.
Previously, Radient's agreement with Uni Pharma provided UniPharma the exclusive right to distribute Radient's flagship product Onko-Sure® cancer test in Taiwan. Radient and UniPharma have now expanded the territory to include Singapore, Hong Kong and Macau. As a full-service distribution partner, UniPharma handles regulatory approvals in assigned territories. Onko-Sure® is a non-invasive in vitro diagnostic blood biomarker test for cancer.
Uni Pharma will be receiving its first shipment of test kits this month, December 2011.
With a combined population of over 35 million people, Taiwan, Singapore, Hong Kong, and Macau is a significant health care market. Cancer remains the leading cause of death in Taiwan, according to the latest statistics released by the Taiwan Department of Health on June 15, 2011 (Taiwan Today, June 16 2011). The most prevalent types of cancer are lung cancer, liver cancer and colorectal cancer, the three of which were responsible for over half of all cancer deaths in Taiwan.
"Onko-Sure® is a cost effective, high value In Vitro Diagnostic cancer test that should be included as a valuable diagnostic tool by doctors, clinicians, and other oncology healthcare professionals," stated Terry Lin, General Manager of UniPharma. "The UniPharma team is excited to distribute Onko-Sure® in our assigned territories of Taiwan and now Singapore, Hong Kong, and Macau. UniPharma has increased its medical sales team and committed to present at upcoming regional cancer conferences to increase awareness of Onko-Sure®. UniPharma has already launched its first Onko-Sure outreach campaign with a booth at the Taiwan Colorectal Cancer Conference at the Taiwan International Convention Center (December 9-11) in Taipei."
"Radient welcomes UniPharma's increased commitment to Onko-Sure®," said the Company's Chairman and CEO, Douglas MacLellan. "We look forward to a continued, successful working relationship as UniPharma advocates the use of Onko-Sure in these important health care markets."
About UniPharma Taiwan:
Founded in 1998, UniPharma was established by a group of professional managers with multi-national pharmaceutical company backgrounds and extensive experience in the pharmaceutical industry. Uni Pharma is dedicated to supplying the best products to patients and delivering the most value to its partners. Uni Pharma distributes pharmaceutical and medical device products in Taiwan for nine international firms from seven countries across the globe. For more information, visit http://www.uni-pharma.com/gyhyenglish.html.
About Radient Pharmaceuticals:
Headquartered in Tustin, California, Radient Pharmaceuticals Corporation is dedicated to saving lives and money for patients and global healthcare systems through the deployment of its FDA-cleared In Vitro Diagnostic Onko-Sure® cancer test kit for colorectal cancer treatment and recurrence monitoring. The Company's focus is on the discovery, development and commercialization of unique high-value diagnostic tests that will help physicians answer important clinical questions related to early disease state detection, treatment strategy, and the monitoring of disease progression or recurrence. Diagnostics are the key to informed treatment decisions; identifying the right treatment for the right patient can make all the difference, particularly in cancer patients. To learn more about our company, products, and potentially life-saving cancer test, visit www.radient-pharma.com.
Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: The statements contained in this document include certain predictions and projections that may be considered forward-looking statements under securities law. These statements involve a number of important risks and uncertainties that could cause actual results to differ materially including, but not limited to, the performance of joint venture partners, as well as other economic, competitive and technological factors involving the Company's operations, markets, services, products, and prices. With respect to Radient Pharmaceuticals Corporation, except for the historical information contained herein, the matters discussed in this document are forward-looking statements involving risks and uncertainties that could cause actual results to differ materially from those in such forward-looking statements.
For additional information on Radient Pharmaceuticals Corporation and its products visit: www.radient-pharma.com or www.onko-sure.com or e-mail email@example.com. For Investor Relations contact Paul Knopick at: firstname.lastname@example.org or 949-707-5365.
SOURCE Radient Pharmaceuticals Corporation